In a historic shift, President Donald Trump has reclassified state-licensed medical marijuana as a less dangerous drug, moving it from Schedule I to Schedule III under the Controlled Substances Act. The change, announced on April 23, 2026, marks the first time the federal government has acknowledged the medical benefits of cannabis at this level.
What the Reclassification Means
The reclassification removes medical marijuana from the most restrictive category of drugs, which includes heroin and LSD, and places it alongside substances like ketamine and Tylenol with codeine. This change is expected to ease research restrictions, reduce tax burdens on cannabis businesses, and potentially lead to further policy shifts at the state level.
Under the new classification, medical marijuana will be recognized as having accepted medical uses and a lower potential for abuse. The decision follows years of advocacy from medical professionals, patients, and industry stakeholders who have argued that the current scheduling hinders scientific study and patient access.
Impact on Research and Industry
Researchers will now face fewer bureaucratic hurdles when studying cannabis for medical purposes. The change also allows cannabis businesses to deduct ordinary business expenses on federal taxes, a benefit previously denied to them under Section 280E of the tax code.
Industry experts predict that the reclassification will boost investment and innovation in the medical marijuana sector. However, it does not legalize recreational use or alter state-level laws. The Drug Enforcement Administration (DEA) will continue to enforce federal regulations regarding cannabis.
Reactions and Next Steps
The announcement has drawn mixed reactions. Supporters, including many in the medical community, hailed it as a long-overdue recognition of cannabis's therapeutic potential. Critics, however, expressed concern that the move could lead to increased use and abuse.
President Trump stated that the decision was based on scientific evidence and public health considerations. The reclassification takes effect immediately, though further rulemaking may be required to implement specific changes.
This policy shift places the United States in line with a growing number of countries that have adopted more lenient cannabis policies. As the implementation unfolds, stakeholders will be watching closely for its effects on medical research, business operations, and patient care.
